RecruitingPhase 2Phase 3NCT07542808

An Open-Label, Double-Treatment Group Study to Evaluate the Efficacy and Safety of Human Allogeneic Bone-Marrow- Derived Mesenchymal Stromal Cell Product StromaForte Compared With Hyaluronic Acid for the Treatment of Knee Osteoarthritis


Sponsor

Cellcolabs Clinical SPV Limited

Enrollment

140 participants

Start Date

Apr 27, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

StromaForte injection for knee OA


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Hyaluronic Acid (HA) and Mesenchymal Stem Cells (MSC) for people with knee arthritis, osteoarthritis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERMesenchymal Stem Cells (MSC)

StromaForte

OTHERHyaluronic Acid (HA)

Hyaluronic Acid


Locations(1)

Burjeel Medical City

Abu Dhabi, United Arab Emirates

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07542808


Related Trials